pembrolizumab,cisplatin,gemcitabine
merck
['pembro']
patients treated with pembrolizumab plus chemotherapy had a median overall survival of 12.7 months compared with 10.9 months among those treated with placebo plus chemotherapy. #aacr23
The mission of the American Association for Cancer Research is to prevent and cure cancer through research, education, communication, and collaboration.